Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Gouw, H W F M
Right arrow Articles by Sterk, P J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Gouw, H W F M
Right arrow Articles by Sterk, P J
Thorax 1999;54:1033-1035 ( November )

Short paper

Effect of oral L-arginine on airway hyperresponsiveness to histamine in asthma H W F M de Gouwa, M B Verbruggena, I M Twissb, P J Sterka

a Department of Pulmonology, b Department of Clinical Pharmacology and Toxicology, c Leiden University Medical Center, Leiden, The Netherlands

Correspondence to: Dr H W F M de Gouw, Lung Function Laboratory, C2-P-62, Leiden University Medical Center, P O Box 9600, NL-2300 RC Leiden, The Netherlands.

Received 26 October 1998; Returned to authors 26 January 1999; Revised version received 4 August 1999; Accepted for publication 4 August 1999

BACKGROUND---Nitric oxide (NO) may exert protective properties within the airways of asthmatic patients. It was postulated that airways obstruction in asthma may be associated with endogenous NO deficiency caused by limited availability of NO synthase substrate.
METHODS---In a double blind, crossover study 14 asthmatic patients received pretreatment with oral L-arginine (50 mg/kg body weight) or placebo prior to histamine challenge. Histamine challenge was performed until a 50% fall in forced expiratory volume in one second (FEV1) occurred and the response was expressed as the provocative concentration causing a 20% fall in FEV1 (PC20) and as the dose-response slope (maximal % fall in FEV1/cumulative dose (µmol)).
RESULTS---Pretreatment with L-arginine did not affect PC20 histamine (mean change in doubling dose 0.18 (95% confidence interval (CI) -0.36 to 0.71), p = 0.5) but the dose-response slope to histamine was slightly reduced (mean change: 0.7 (95% CI 0.6 to 0.9), p = 0.016).
CONCLUSIONS---Oral L-arginine does not influence airway hyperresponsiveness to histamine as reflected by PC20, although the dose-response slope is slightly reduced in patients with asthma. This indicates only marginal, clinically unimportant limitation of NO synthase substrate in asthma.


Keywords: nitric oxide; asthma; airway hyperresponsiveness

© 1999 by Thorax


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Maarsingh, A. B. Zuidhof, I. S. T. Bos, M. van Duin, J.-L. Boucher, J. Zaagsma, and H. Meurs
Arginase Inhibition Protects against Allergen-induced Airway Obstruction, Hyperresponsiveness, and Inflammation
Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 565 - 573.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
H. W. F. M. De Gouw, S. J. Marshall-Partridge, H. Van der Veen, J. G. Van den Aardweg, P. S. Hiemstra, and P. J. Sterk
Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects
J Appl Physiol, February 1, 2001; 90(2): 586 - 592.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1999 BMJ Publishing Group Ltd & British Thoracic Society